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Abstract: Heparin-based anticoagulants are drugs of choice in the therapy and prophylaxis of 
thromboembolic diseases. Idraparinux is a synthetic anticoagulant pentasaccharide based on the 
heparin antithrombin-binding domain. In the frame of our ongoing research aimed at the synthesis 
of sulfonic acid-containing heparinoid anticoagulants, we elaborated a modular pathway to obtain 
a series of idraparinux-analogue pentasaccharides bearing one or two primary sulfonic acid moieties. 
Five protected pentasaccharides with different C-sulfonation patterns were prepared by two 
subsequent glycosylation reactions, respectively, using two monosaccharide and four disaccharide 
building blocks. Transformation of the protected derivatives into the fully O-sulfated, O-methylated 
sulfonic acid end-products was also studied. 
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1. Introduction 
Venous and arterial thromboembolic disorders, including pulmonary embolism and deep vein 
thrombosis represent a serious medical and socioeconomic problem worldwide. Untreated 
thromboembolism leads to cardiac or cerebral infarction or, in more severe cases, to death. 
Anticoagulants are used in the prevention and treatment of venous thrombosis and in the prevention 
of systemic embolism [1–4]. The sulfated polysaccharide heparin and its fractionated derivatives have 
successfully been used in anticoagulant therapy and thromboprophylaxis since the late 1930s until 
today. Heparin derivatives indirectly inhibit the coagulation enzymes thrombin or factor Xa through 
activation of the serine protease inhibitor antithrombin, which is an endogenous regulatory protein 
in the coagulation cascade [5]. Despite their effectiveness in therapy, heparin polysaccharides may 
incur side effects including inflammation, bleeding or heparin induced thrombocytopenia (HIT) due 
to its highly polyanionic and heterogeneous nature [6]. 
After the antithrombin-binding pentasaccharide domain of heparin (1), termed DEFGH, was 
identified, its closely related synthetic analogue, fondaparinux 2, has been developed into a novel 
antithrombotic under the name Arixtra [7,8]. This pentasaccharide selectively inhibits factor Xa and 
minimizes the bleeding risk and many other unfavorable factors in anticoagulant therapy. Further 
research efforts led to the development of the non-glycosaminoglycan derivative, idraparinux 3 [9], 
possessing a simplified structure and an increased anticoagulant activity compared to Arixtra. 
The interaction between heparin and antithrombin are primarily mediated by negatively 
charged groups of heparin and the positively charged lysine and arginine residues from the protein. 
Structure-activity relationship (SAR) studies of synthetic analogues of heparin pentasaccharides 
revealed that the type of negative charge is crucial; the carboxylate groups cannot be exchanged for 
Molecules 2016, 21, 1497 2 of 18 
 
sulfate esters, and sulfate moieties cannot be exchanged for phosphate groups without destroying 
the anticoagulant activity [1,3]. 
With the aim of developing a novel class of heparinoid anticoagulants, our group has started a 
programme to study whether the sulfate ester groups of the active pentasaccharide can be exchanged 
with sulfonic acid moieties without detriment to the antithrombin-binding ability [10–19]. Two 
pentasaccharide sulfonic acids (4 and 5) and the reference compound idraparinux 3 have been prepared 
until now. An in vitro coagulation study of 2–5 clearly demonstrated that the position and/or number 
of the sulfonic acid moieties have a substantial impact on the anticoagulant activity (Figure 1). While 
the disulfonate analogue 4 displayed higher activity than the reference compounds 2 and 3, the 
introduction of a third sulfonic-acid moiety to the terminal sugar unit of compound 5 resulted in a 
dramatic decrease in anti-Xa activity [14]. The difference in the biological activity of the disulfonic 
and trisulfonic acids was attributed to the different conformation of their L-iduronic-acid residues. 
 
Compound Anti-Xa Activity (U/mg) 
Arixtra (2) 1195 ± 189 
Idraparinux (3) 1911 ± 193 
Pentasaccharide disulfonic acid 4 2153 ± 153 
Pentasaccharide trisulfonic acid 5 384 ± 139 
Figure 1. The antithrombin-binding pentasaccharide domain of heparin (1) and structures and factor 
Xa inhibitory activities of the synthetic analogues 2–5. 
These results prompted us to prepare a series of heparinoid pentasaccharides by systematic 
replacement of the sulfate esters with a sodium sulfonatomethyl moiety for further structure-activity 
relationship studies. To get an easy access to all possible sulfonic acid isosters of idraparinux bearing 
the sulfonic acid moieties at primary positions, we elaborated a modular synthetic pathway based on 
the retrosynthetic analysis of the targeted pentasaccharides (Figure 2). According to this modular 
approach, the synthesis of all planned pentasaccharide sulfonic acids could be accomplished by using two 
DE disaccharide donors, two F building blocks and two GH disaccharide acceptors. Multigram-scale 
syntheses of the 6-deoxy-6-sulfonatomethyl-containing F, DE and GH building blocks have been 
published recently [17]. Herein, we present the synthesis of the FGH acceptors and assembly of five 
protected pentasaccharide sulfonic acids via [2 + 3] block syntheses. Our study to convert the protected 
mono- and disulfonic acid derivatives into the corresponding fully O-sulfated and O-methylated  
end-products via two different reaction sequences is also described. 
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Figure 2. Retrosynthetic analysis for modular [2 + 3] block syntheses of the targeted pentasaccharide 
sulfonic acids 6–10. 
2. Results and Discussion 
2.1. Synthesis of the Protected Pentasaccharides 
The synthetic route to the FGH trisaccharide acceptors 20–22 is shown in Scheme 1. First, the L-
idose-containing diol 11 [18] was converted to iduronide acceptor 12 by selective oxidation using 
(2,2,6,6-tetramethylpiperidin-1-yl)oxyl (TEMPO) as the oxidant and [bis(acetoxy)iodo]benzene (BAIB) as 
the co-oxidant [20,21]. The corresponding sulfonic acid isoster 14 [17] was prepared from 13 [17] in 
an analogous way. Next, GH disaccharide acceptors 12 and 14 were reacted with F monosaccharide 
donors 15 [16] and 16 [18], respectively, in the presence of N-iodosuccinimide (NIS) and 
trifluoromethanesulfonic acid (TfOH). This promoter system proved to be highly efficient for 
stereoselective condensation of the phenylthio-glucoside donor 16 with either of the acceptors, and 
the corresponding trisaccharides 18 and 19, with the required α-interglycosidic linkage, were 
obtained in 98% and 80% yields, respectively. NIS-TfOH-promoted glycosylation of 12 with the 
sulfonatomethyl donor 15 also occurred with full α-selectivity affording trisaccharide 17 as the only 
product. However, the yield was moderate due to insufficient conversion of the acceptor. 
Fortunately, by changing the promotors to NIS-AgOTf, the conversion could significantly be 
increased, and the yield of 17 reached 73%. Liberation of the 4-OH group of the terminal glucose unit 
of the fully protected trisaccharides 17–19 was accomplished by oxidative removal of the (2-naphthyl) 
methyl (NAP) group using 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) as the reagent [22,23], 
furnishing the FGH acceptors 20–22 in good to excellent yields. 
To avoid inefﬁcient glycosylations with glucuronic acid donors of inherent low reactivity, which 
were observed in earlier syntheses [9,15,24], donors 23 [17] and 24 [13] containing a non-oxidized 
precursor of the glucuronide unit were used for [2 + 3] block syntheses of the targeted pentasaccharides 
(Scheme 2). Condensation reactions of the trisaccharide acceptors 20–22 with the disaccharide donors 23 
and 24 were carried out upon NIS-AgOTf or NIS-TfOH activation, respectively. All reactions took place 
in a stereoselective way providing the protected pentasaccharides 6–10, with the required β-linkage 
between units E and F, in good yields. 
Molecules 2016, 21, 1497 4 of 18 
 
 
Scheme 1. Preparation of the FGH building blocks. 
 
Scheme 2. Synthesis of the protected pentasaccharide derivatives. 
2.2. Transformation of the Protected Pentasaccharides into the End-Products 
Transformation of compounds 6–10 into the fully O-methylated and O-sulfated mono- and 
disulfonic acid end-products requires eight further synthetic steps including acetyl-, NAP- and 
benzyl-deprotections, formation of the glucuronic acid unit, liberation of carboxylic and sulfonic 
esters and the introduction of methyl ether and sulfate ester functions. We envisioned a reaction sequence 
in which the introduction of methyl ethers precedes the oxidative formation of the glucuronide residue 
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E. To study the efficacy of this procedure, compound 9 was subjected to Zemplén deacetylation to 
liberate the hydroxyls to be methylated (Scheme 3). Upon deacetylation with NaOMe, nucleophilic 
cleavage of the sulfonic-acid ester of unit F also occurred in some extent. Hence, the obtaining mixture 
of the sulfonate ester and sodium sulfonate derivatives was unified by treating with sodium iodide 
in acetone to give sulfonic acid salt 25 in an 81% yield over two steps. Introduction of the methyl 
ethers to the liberated hydroxyls was accomplished by alkylation using methyl iodide and sodium 
hydride to afford the desired 26 in a 67% yield. Subsequently, the 6-position of the penultimate 
glucose unit was unmasked by oxidative de-O-(2-napthyl)methylation to produce 27 in 80%. 
TEMPO-BAIB mediated oxidation of 27 proceeded slowly and required large amounts of the co-
oxidant BAIB to eventually produce, after 48 h, the glucuronide derivative 28, along with its partially 
debenzylated derivatives. Compound 28 could not be separated from the by-products, thus, this mixture 
was subjected to the remaining transformation, including basic hydrolysis of the iduronic ester, catalytic 
hydrogenolysis and O-sulfation to furnish 29, a monosulfonic acid analogue of idraparinux. 
 
Scheme 3. Transformation of 9 into final product 29, a novel sulfonic acid analogue of idraparinux. 
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For conversion of 6 into the final sulfated analogue, another reaction sequence, starting with the 
formation of the glucuronide residue, was used. The NAP protecting group of unit E was cleaved 
with DDQ to afford 30. Oxidation of the liberated 6-OH by TEMPO and BAIB proceeded smoothly 
to provide the required glucuronic acid-containing pentasaccharide 31 in 80%. Zemplén deacetylation 
followed by deprotection of the sulfonic acid esters by nucleophilic displacement with sodium iodide 
gave the trisodium salt 32. Methylation of the free hydroxyl groups by using methyl iodide and 
sodium hydride afforded the desired 33, which possessed all of the required methyl ethers. 
Deprotection of the carboxylic-ester group of 33 by saponification gave tetrasodium salt 34, de-O-
benzylation of which, by catalytic hydrogenolysis, furnished compound 35 in a high yield. O-
Sulfation of the pentaol by using SO3·Et3N was surprisingly sluggish and the use of a high excess 
reagent and a prolonged reaction time were needed for completion of the sulfate ester formation. 
Finally, the reaction gave, after treatment with Dowex Na+ ion-exchange resin, compound 36 as a new 
isosteric disulfonic acid analogue of idraparinux (Scheme 4). 
 
Scheme 4. Transformation of 6 into the corresponding pentasaccharide disulfonic acid final product. 
3. Materials and Methods 
3.1. General Information 
Optical rotations were measured at room temperature with a Perkin-Elmer 241 automatic 
polarimeter. Thin layer chromatography (TLC) was performed on Kieselgel 60 F254 (Merck) with 
detection by immersing into 5% ethanolic sulfuric acid solution followed by heating. Column 
chromatography was performed on Silica gel 60 (Merck 0.063–0.200 mm). Organic solutions were 
dried over MgSO4, and concentrated in a vacuum. The 1H-NMR (360 and 400 MHz) and 13C-NMR 
(90.54 and 100.28 MHz) spectra were recorded with Bruker DRX-360 and DRX-400 spectrometers at 
25 °C. Chemical shifts are referenced to Me4Si or 4,4-dimethyl-4-silapentane-1-sulfonic acid (DSS) 
(0.00 ppm for 1H) and to the solvent signals (CDCl3: 77.00 ppm for 13C). The 1H- and 13C-NMR 
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assignments have been established from 1D-NMR spectra and for compounds 6, 7, 8, 9, 10, 20 and 21 
the proton-signal assignments were supported by analysis of two-dimensional 1H–1H correlation 
spectra (COSY), as well as the carbon-signal assignments by two-dimensional 13C–1H correlation 
maps (HSQC). Infrared (IR) spectra were recorded on a Perkin–Elmer 16 PC FTIR (Program counter 
Fourier transform infrared) spectrometer. Matrix-assisted laser desorption/ionization-time-of-flight 
mass spectrometric (MALDI-TOF MS analyses of the compounds were carried out in the positive 
reflectron mode using a BIFLEX III mass 13 spectrometer (Bruker, Rheinstetten, Germany) equipped 
with delayed-ion extraction. The matrix solution was a saturated 2,4,6-trihydroxy-acetophenone 
(THAP) solution in MeCN. Elemental analyses (C, H, S) were performed using an Elementar Vario 
MicroCube instrument.  
3.2. General Method A for TEMPO-BAIB Oxidation (12, 28, 31) 
To a vigorously stirred solution of the appropriate alcohol (1 mmol) in CH2Cl2 (3.5 mL) and H2O 
(1.5 mL), TEMPO (0.2 mmol) and BAIB (2 mmol) were added and the reaction mixture was stirred 
until TLC showed complete conversion of the starting material. The reaction time was 45 min for 12, 
24 h for 31 and 48 h for 28. The reaction mixture was quenched by the addition of 10% aq Na2S2O3 
solution (20 mL). The mixture was then extracted twice with EtOAc (10 mL), and the combined 
organic layers were dried, and concentrated. 
3.3. General Method B for Glycosylation Reaction Using NIS-TfOH Promoter System (7, 17, 18, 19) 
To a solution of donor (1.5 mmol) and acceptor (1 mmol) in dry CH2Cl2 (20 mL), 4 Å molecular 
sieves were added. The stirred mixture was cooled to −60 °C (17, 18, 19) and −50 °C (7) under argon. 
After 30 min at this temperature, NIS (2.25 mmol) and TfOH (0.045 mmol) dissolved in THF (155 μL) 
were added. The temperature was increased to −50 °C (17, 18, 19) or −20 °C (7). The reaction mixture 
was quenched with Et3N (50 μL), diluted with CH2Cl2 (100 mL) and the reaction mixture was 
extracted with saturated Na2S2O3 solution (20 mL), saturated NaHCO3 solution (20 mL) and with 
distilled water (20 mL). The organic phase was dried and concentrated. 
3.4. General Method C for Glycosylation Using NIS-AgOTf Promoter System (6, 8, 9, 10, 17) 
To a solution of acceptor (1 mmol) and donor (1.5 mmol) in dry CH2Cl2 (20 mL), 4 Å molecular 
sieves were added. The stirred mixture was cooled to between −60 °C and −35 °C under argon. After 
30 min at this temperature, 2.25 mmol NIS dissolved in THF (1 mL) and 0.36 mmol AgOTf dissolved 
in toluene (1 mL) were added. After 1–4 h stirring at −50 °C (17), −20 °C (9), −15 °C (6), −10 °C (10) or 
0 °C (8) Et3N (50 μL) was added. The reaction mixture was diluted with CH2Cl2 (100 mL) and filtered 
through a pad of Celite. The filtrate was concentrated. 
3.5. General Method D for Removal of the (2-Naphthyl)methyl Ether Group (20, 21, 22, 27, 30) 
To a vigorously stirred solution of starting material (1 mmol) in CH2Cl2: H2O (9:1, 10 mL) DDQ 
(1.5 mmol) was added. The reaction mixture was stirred at room temperature for 30–40 min, diluted 
with CH2Cl2 (30 mL), washed successively with satd aq NaHCO3 solution (15 mL) and H2O (15 mL). 
The organic phase was dried and concentrated. 
3.6. Product Characterization 
Methyl [methyl (2-O-acetyl-3-O-methyl-α-L-idopyranosyl)uronate](1→4)-2,3,4-tri-O-benzyl-α-D-glucopyranoside 
(12). The starting material 11 [18] (3.20 g, 4.7 mmol) was oxidized according to general method A. 
The crude uronic acid was dissolved in THF (4.5 mL) and treated with ethereal diazomethane at 0 
°C. After complete disappearance of the uronic acid, the mixture was concentrated. The crude 
product was purified by column chromatography to give 12 (2.47 g, 74%) as a colourless syrup; Rf = 
0.36 (7:3 n-hexane/acetone); [α]D −2.67 (c 1.00, CHCl3); IR νmax (KBr): 3480, 3474, 3031, 2936, 2902, 1744, 
1633, 1496, 1454, 1372, 1225, 1167, 1103, 1045, 911, 890, 854, 740, 700, 605 cm−1; 1H-NMR (360 MHz, 
CDCl3) δ 7.37–7.20 (m, 15H, arom.), 5.08 (s, 1H), 4.98 (d, J = 11.4 Hz, 2H), 4.87 (s, 1H), 4.81 (d, J = 11.4 
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Hz, 1H, PhCH2), 4.67 (d, J = 12.0 Hz, 1H, PhCH2), 4.56–4.49 (m, 4H), 3.99–3.80 (m, 3H), 3.78–3.70 (m, 
2H), 3.67–3.62 (m, 1H), 3.57 (dd, J = 9.4, 3.6 Hz, 1H), 3.50–3.44 (m, 1H), 3.47, 3.40, 3.34 (3s, 9H, 3 × CH3), 
2.68 (d, J = 11.8 Hz, 1H, OH), 2.01 (s, 3H, COCH3) ppm; 13C-NMR (91 MHz, CDCl3) δ 169.7, 169.2 
(COOCH3, COCH3), 139.0, 138.0, 138.0 (3C, Cq arom.), 128.4, 128.4, 128.2, 128.1, 127.9, 127.6, 127.6, 
127.2, 127.0 (15C, arom.), 98.0, 97.6 (C-1-H, C-1-G), 80.3, 79.7, 76.8, 74.7, 70.1, 68.0, 67.2, 67.1 (C-2-G, 
C-2-H, C-3-G, C-3-H, C 4 G, C-4-H, C-5-G, C-5-H), 74.8, 73.4, 73.3 (3 × PhCH2), 68.5 (C-6-H), 58.1 
(OCH3, C-3-G), 55.2 (OCH3, C-1-H), 51.9 (COOCH3), 21.00 (COCH3) ppm; MALDI-TOF MS: m/z 733.16 
[M + Na]+ (Calcd. 733.28); Anal. Calcd. for C38H46O13 (710.29): C, 64.21; H, 6.52; O, 29.26. Found: C, 
64.28; H, 6.55. 
Methyl [2,3-di-O-Benzyl-4-O-(2-naphthyl)methyl-6-deoxy-6-C-(ethylsulfonatomethyl)-α-D-glucopyranosyl]-
(1→4)-[methyl (2-O-acetyl-3-O-methyl-α-L-idopyranosyl)uronate]-(1→4)-(2,3,6-tri-O-benzyl-α-D-
glucopyranoside) (17) 
I. To a solution of acceptor 12 (2.80 g, 3.94 mmol) and donor 15 [16] (3.85 g, 5.91 mmol) in dry 
CH2Cl2 (20 mL), 4 Å molecular sieves (0.50 g) were added. The stirred mixture was cooled to −60 °C 
under argon and activated by method B. The reaction mixture was allowed to warm up to −50 °C in 
1 h. The crude product was purified by column chromatography (7:3 n-hexane/EtOAc) to give 17 
(2.35 g, 46%). Unreacted 12 (1.11 g, 28%) was recovered as a colourless syrup. 
II. To a solution of acceptor 12 (1.11 g, 1.41 mmol) and donor 15 (1.37 g, 2.11 mmol) in dry CH2Cl2 
(20 mL), 4 Å molecular sieves (0.50 g) were added. The stirred mixture was cooled to −60 °C under 
argon and activated by method C. The reaction mixture was allowed to warm up to −50 °C for 1 h. 
The crude product was purified by column chromatography (7:3 n-hexane/EtOAc) to give 17 (1.47 g, 
73%) as a white foam; Rf = 0.34 (6:4 n-hexane/EtOAc); [α]D +11.30 (c 0.81, CHCl3); IR νmax (KBr): 3447, 
3087, 3061, 3030, 2933, 1763, 1737, 1636, 1604, 1497, 1455, 1369, 1357, 1238, 1169, 1107, 1028, 1002, 917, 
857 cm−1; 1H-NMR (360 MHz, CDCl3) δ 7.83–7.66 (m, 4H, arom.), 7.49–7.42 (m, 2H, arom.), 7.39–7.16 
(m, 26H, arom.), 5.13 (s, 1H), 5.03 (d, J = 11.3 Hz, 1H, ArCH2), 4.93 (m, 2H), 4.85–4.72 (m, 7H), 4.66 (t, 
J = 12.6 Hz, 2H), 4.60–4.54 (m, 3H), 4.12 (q, J = 7.1 Hz, 2H, SO3CH2CH3), 3.96–3.61 (m, 9H), 3.54 (dd, J 
= 9.4, 3.5 Hz, 1H), 3.44–3.34 (m, 1H), 3.41, 3.36, 3.34 (3s, 9H, 3 × OCH3), 3.24–3.05 (m, 3H), 2.36–2.24 
(m, 1H, H-7a), 2.00–1.83 (m, 4H, COCH3, H-7b), 1.25 (t, J = 7.1 Hz, 3H, SO3CH2CH3) ppm; 13C-NMR (91 
MHz, CDCl3) δ 170.1, 169.4 (2 × CO), 139.1, 138.4, 138.1, 138.1, 138.1, 135.6, 133.3, 133.0 (8C, Cq arom.), 
128.6, 128.5, 128.4, 128.4, 128.2, 128.2, 128.0, 127.9, 127.9, 127.7, 127.6, 127.3, 127.1, 126.5, 126.2, 126.0, 
125.7 (32C, arom.), 98.7, 98.0, 97.7 (3 × C-1), 81.5, 81.2, 80.4, 80.2, 79.8, 76.5, 74.7, 74.7, 70.1, 69.5, 68.3, 
67.7 (12C, skeleton carbons), 75.5, 75.1, 74.9, 73.6, 73.4, 73.4 (6 × ArCH2), 68.5 (C-6-F), 66.2 
(SO3CH2CH3), 58.3, 55.2, 51.8 (3 × OCH3), 46.5 (C-7-H), 25.9 (C-6-H), 21.1 (COCH3), 15.1 (SO3CH2CH3) 
ppm; MALDI-TOF MS: m/z 1321.57 [M + Na]+ (Calcd. 1321.50); Anal. Calcd. for C72H82O20S (1298.51): 
C, 66.55; H, 6.36; O, 24.62; S, 2.47. Found: C, 66.62; H, 6.40; S, 2.45. 
Methyl [2,3,6-tri-O-benzyl-4-O-(2-naphthyl)methyl-α-D-glucopyranosyl]-(1→4)-[methyl (2-O-acetyl-3-O-methy- 
α-L-idopyranosyl)uronate]-(1→4)-2,3-di-O-benzyl-6-deoxy-6-C-(ethylsulfonatomethyl)-α-D-glucopyranoside 18. 
To a solution of acceptor (14) [17] (620 mg, 0.85 mmol) and donor 16 [17] (874 mg, 1.28 mmol) in dry 
CH2Cl2 (20 mL) 4 Å molecular sieves (0.50 g) were added. The stirred mixture was cooled to −60 °C 
under argon and activated by method B. The reaction mixture was allowed to warm up to −50 °C for 
1 h. The crude product was purified by column chromatography (7:3 n-hexane/EtOAc) to give 18 
(1.07 g, 98%) as a white foam; Rf = 0.63 (1:1 n-hexane/ EtOAc); [α]D +6.62 (c 0.35, CHCl3); IR νmax (KBr): 
3446, 3087, 3061, 3030, 2931, 2869, 1739, 1636, 1604, 1497, 1455, 1362, 1236, 1165, 1107, 1045, 1028, 1004, 
917, 857, 818 cm−1; 1H-NMR (360 MHz, CDCl3) δ 7.85–7.67 (m, 3H, arom.), 7.55 (s, 1H, arom), 7.49–7.41 
(m, 2H, arom.), 7.38–7.14 (m, 26H, arom.), 5.25 (s, 1H), 4.99–4.35 (m, 16H), 4.27 (q, J = 7.1 Hz, 2H, 
SO3CH2CH3), 3.97–3.63 (m, 7H), 3.62–3.24 (m, 4H), 3.47, 3.40, 3.32 (3 × OCH3), 3.16–3.04 (m, 1H), 2.44–
2.32 (m, 1H, H-7a), 2.03 (s, 3H, COCH3), 2.01–1.85 (m, 1H, H-7b), 1.37 (t, 3H, SO3CH2CH3) ppm; 13C-
NMR (91 MHz, CDCl3) δ 170.2, 169.6 (2 × CO), 139.0, 138.7, 138.3, 138.1, 138.0, 136.3, 133.3, 132.9 (8C, 
Cq arom.), 128.5, 128.4, 128.2, 128.1, 128.0, 127.9, 127.7, 127.2, 126.1, 125.9, 125.8, 125.6 (32C, arom.), 
99.6, 98.0, 98.0 (3 × C-1), 81.8, 80.3, 80.0, 79.5, 78.6, 77.0, 75.1, 71.4, 69.2, 68.4, 68.1, 57.9 (12C, skeleton 
carbons), 75.5, 75.2, 74.7, 73.5, 73.5, 73.4 (6 × ArCH2), 68.1 (C-6-H), 66.2 (SO3CH2CH3), 58.7, 55.6, 51.9 
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(3 × OCH3), 46.7 (C-7-F), 26.0 (C-6-F), 21.1 (COCH3), 15.2 (SO3CH2CH3) ppm; MALDI-TOF MS: m/z 
1321.57 [M + Na]+ (Calcd. 1321.50); Anal. Calcd. for C72H82O20S (1298.51): C, 66.55; H, 6.36; O, 24.62; S, 
2.47. Found: C, 66.50; H, 6.42; S, 2.51. 
Methyl [2,3,6-tri-O-benzyl-4-O-(2-naphthyl)methyl-α-D-glucopyranosyl]-(1→4)-[methyl (2-O-acetyl-3-O-methyl 
-α-L-idopyranosyl)uronate]-(1→4)-(2,3,6-tri-O-benzyl-α-D-glucopyranoside) (19). To a solution of acceptor 
12 (1.50 g, 2.10 mmol) and donor 16 (2.16 g, 3.16 mmol) in dry CH2Cl2 (20 mL) 4 Å molecular sieves 
(0.50 g) were added. The stirred mixture was cooled to −60 °C under argon and activated by method 
B. The reaction mixture was allowed to warm up to −50 °C for 30 min. The crude product was purified 
by column chromatography (7:3 n-hexane/EtOAc) to give 18 (2.41 g, 80%) as a white foam. Rf = 0.47 
(6:4 n-hexane/EtOAc). 
Methyl [2,3-di-O-benzyl-6-deoxy-6-C-(ethylsulfonatomethyl)-α-D-glucopyranosyl]-(1→4)-[methyl (2-O-acetyl-3- 
O-methyl-α-L-idopyranosyl)uronate]-(1→4)-(2,3,6-tri-O-benzyl-α-D-glucopyranoside) (20). Compound 17 
(2.50 g, 1.92 mmol) was converted to 20 according to general method D. The crude product was 
purified by column chromatography (7:3 n-hexane/EtOAc) to give compound 20 (1.55 g, 70%) as a 
white foam; Rf = 0.40 (1:1 n-hexane/EtOAc); [α]D +13.46 (c 0.56, CHCl3); IR νmax (KBr): 3502, 3088, 3063, 
3031, 2933, 1738, 1629, 1497, 1455, 1370, 1356, 1236, 1168, 1108, 1047, 1028, 917, 820, 740, 698, 606, 545, 
466 cm−1; 1H-NMR (400 MHz, CDCl3) δ 7.38–7.19 (m, 25H, arom.), 5.15 (s, 1H, H-1-G), 4.93 (d, J = 11.4 
Hz, 2H, BnCH2), 4.85–4.76 (m, 4H, H-2-G, H-5-G, H-1-F, BnCH2), 4.75–4.61 (m, 4H, BnCH2), 4.55 (m, 
3H, H-1-H, BnCH2), 4.24 (q, J = 7.1 Hz, 2H, SO3CH2CH3), 3.94–3.79 (m, 3H, H-3-H, H-4-G), 3.77–3.59 
(m, 6H, H-3-G, H-3-F, H-5-F, H-4-H, H-6a,b-H), 3.54 (dd, J = 9.3, 3.5 Hz, 1H, H-2-H), 3.43–3.31 (m, 2H, 
H-2-F, H-5-H), 3.40, 3.37, 3.34 (3s, 3 × CH3) 3.28–3.09 (m, 3H, H-4-F, H-7a,b), 2.48 (s, 1H, OH), 2.33–2.21 
(m, 1H, H-6a-F), 1.93 (s, 3H, COCH3), 1.98–1.84 (m, 1H, H-6b-F), 1.35 (t, J = 7.1 Hz, 3H, SO3CH2CH3) 
ppm; 13C-NMR (101 MHz, CDCl3) δ 170.0, 169.3 (2 × CO), 139.1, 138.5, 138.1, 138.0, 137.9 (5C, Cq arom.), 
128.6, 128.5, 128.4, 128.3, 128.1, 128.1, 128.0, 127.9, 127.8, 127.8, 127.7, 127.5, 127.3, 127.1 (25C, arom.), 
98.5 (C-1-F), 98.0 (C-1-H), 97.7 (C-1-G), 80.6 (C-3-F), 80.1 (C-2-H), 79.9 (C-2-F), 79.8 (C-3-H), 79.8 (C-4-
G), 76.5 (C-5-F), 74.8 (C-2-G), 74.4 (C-4-F), 75.0, 74.9, 73.4, 73.3, 73.2 (5 × PhCH2), 70.1 (C-4-H), 69.8 (C-
5-H), 68.5 (C-3-F), 68.4 (C-6-H), 68.0 (C-5-G), 66.2 (SO3CH2CH3), 58.4, 55.2, 51.7 (3 × OCH3), 46.3 (C-7-
F), 25.8 (C-6-F), 21.0 (COCH3), 15.1 (SO3CH2CH3) ppm; MALDI-TOF MS: m/z 1181.59 [M + Na]+ (Calcd. 
1181.44); Anal. Calcd. for C61H74O20S (1158.45): C, 63.20; H, 6.43; O, 27.60; S, 2.77. Found: C, 63.25; H, 
6.37; S, 2.72. 
Methyl [2,3,6-tri-O-benzyl-α-D-glucopyranosyl]-(1→4)-[methyl(2-O-acetyl-3-O-methyl-α-L-idopyranosyl)uronate]- 
(1→4)-2,3-di-O-benzyl-6-deoxy-6-C-(ethylsulfonatomethyl)-α-D-glucopyranoside (21). Compound 18 (1.06 
g, 0.83 mmol) was converted to 21 according to general method D. The crude product was purified 
by column chromatography (65:35 n-hexane/acetone) to give compound 21 (807 mg, 85%) as a white 
foam; Rf = 0.38 (65:35 n-hexane/acetone); [α]D +14.44 (c 0.04, CHCl3); IR νmax (KBr): 3481, 3063, 3031, 
2929, 1740, 1626, 1497, 1455, 1370, 1234, 1167, 1105, 1046, 1028, 926, 820, 739, 698, 606, 548, 460, 418 
cm−1; 1H-NMR (400 MHz, CDCl3) δ 7.30–7.08 (m, 25H, arom.), 5.17 (d, J = 3.3 Hz, 1H, H-1-G), 4.86–
4.65 (m, 3H, H-1-F, H-2-G, H-5-G, BnCH2), 4.59 (m, 3H, BnCH2), 4.50–4.34 (m, 4H, H-1-H, BnCH2), 
4.18 (q, J = 7.1 Hz, 2H, SO3CH2CH3), 3.85–3.14 (m, 13H, skeleton protons), 3.36, 3.29, 3.23 (3s, 9H, 
OCH3), 3.05–2.95 (m, 1H, H-7b-H), 2.46 (s, 1H, OH), 2.34–2.24 (m, 1H, H-6a-H), 1.93 (s, 3H, COCH3), 
1.89–1.76 (m, 1H, H-6b-H), 1.28 (t, J = 7.1 Hz, 3H, SO3CH2CH3) ppm; 13C-NMR (101 MHz, CDCl3) δ 
170.2, 169.6 (2 × CO), 139.0, 138.8, 138.2, 138.1, 138.0 (5C, Cq arom.), 128.6, 128.5, 128.4, 128.2, 128.0, 
127.9, 127.8, 127.8, 127.3 (25C, arom.), 99.5 (C-1-F), 98.1 (C-1-H), 98.0 (C-1-G), 81.1, 80.2, 79.5, 79.5, 78.9, 
77.0, 75.0, 71.2, 70.9, 69.8 (12C, skeleton carbons), 75.3, 75.1,73.7, 73.6, 73.3 (5 × PhCH2), 69.3 (C-6-F), 
69.0, 68.2, 66.3 (SO3CH2CH3), 58.9, 55.6, 51.9 (3 × OCH3), 46.8 (C-7-H), 25.9 (C-6-H), 21.1 (COCH3), 15.2 
(SO3CH2CH3) ppm; MALDI-TOF MS: m/z 1181.64 [M + Na]+ (Calcd. 1181.44); Anal. Calcd. for 
C61H74O20S (1158.45): C, 63.20; H, 6.43; O, 27.60; S, 2.77. Found: C, 63.34; H, 6.47; S, 2.79. 
Methyl [2,3,6-tri-O-benzyl-α-D-glucopyranosyl]-(1→4)-[methyl-(2-O-acetyl-3-O-methyl-α-L-idopyranosyl)uronate]- 
(1→4)-(2,3,6-tri-O-benzyl-α-D-glucopyranoside) (22) [15]. Compound 19 (2.4 g, 1.87 mmol) was 
converted to 22 according to general method D. The crude product was purified by column 
chromatography (7:3 n-hexane/EtOAc) to give compound 22 (1.26 g, 59%) as a white foam; Rf = 0.33 (6:4 
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n-hexane/EtOAc); [α]D +8.41 (c 0.62, CHCl3) (lit. [15] [α]D +2.3 (c 0.10, CHCl3); IR νmax (KBr): 3087, 3062, 
3031, 2932, 2906, 1739, 1605, 1497, 1455, 1371, 1237, 1104, 1046, 1028, 908, 738, 697, 606, 538, 459, 419 
cm−1. The NMR spectroscopic and analytical data of 22 are consistent with those given in the literature 
[15]. 
Methyl [2,3,4-tri-O-methyl-6-deoxy-6-C-(ethylsulfonatomethyl)-α-D-glucoopiranosyl]-(1→4)-[2,3-di-O-acetyl-6-
O-(2-naphthyl)methyl-β-D-glucopyranosyl]-(1→4)-[2,3-di-O-benzyl-6-deoxy-6-C-(ethylsulfonatomethyl)-α-D-
glucopyranosyl]-(1→4)-[methyl (2-O-acetyl-3-O-methyl-α-L-idopyranosyl)uronate]-(1→4)-2,3,6-tri-O-benzyl-
α-D-gluco-pyranoside (6).To a solution of acceptor 20 (630 mg, 0.54 mmol) and donor 23 (660 mg, 0.82 
mmol) in dry CH2Cl2 (20 mL), 4 Å molecular sieves (0.50 g) were added. The stirred mixture was 
cooled to −40 °C under argon and activated by method C. The reaction mixture was allowed to warm up 
to −15 °C for 4 h. The crude product was purified by column chromatography (6:4 n-hexane/EtOAc) to 
give 6 (626 mg, 62%) as a colourless syrup; Rf = 0.26 (1:1 n-hexane/EtOAc); [α]D +23.69 (c 0.14, CHCl3); 
1H-NMR (400 MHz, CDCl3) δ 7.84–7.75 (m, 3H, arom.), 7.65 (s, 1H, arom.), 7.48–7.40 (m, 2H, arom.), 
7.37–7.13 (m, 26H, arom.), 5.18 (t, J = 9.2 Hz, 1H, H-3-E), 5.11 (s, 1H, H-1-G), 4.99–4.46 (m, 19H, H-1-
D, H-2-E, H-5-G, H-2-G, H-1-E, H-1-H, H-1-F, 12 × ArCH2), 4.27, 4.07 (2q, 4H, SO3CH2CH3), 3.93–3.77 
(m, 5H, H-4-H, H-4-E, H-3-F, H-4-G, H-3-H), 3.76–3.59 (m, 5H, H-5-H, H-5-F, H-6a,b-H, H-3-G), 3.58–3.17 
(m, 9H, H-2-F, H-6a,b-E, H-5-D, H-4-F, H-2-H, H-3-D, H-5-E, H-7a-F), 3.52, 3.48, 3.40, 3.36, 3.33, 3.31 
(6s, 18H, 6 × OCH3), 3.18–3.03 (m, 2H, H-7b-F, H-7a-D), 2.93–2.81 (m, 2H, H-2-D, H-7b-D), 2.65 (t,  
J = 9.2 Hz, 1H, H-4-D), 2.33–2.21 (m, 1H, H-6a-F), 2.21–2.08 (m, 1H, H-6a-D), 2.05, 1.99, 1.94 (3s, 9H, 3 
× COCH3), 1.86–1.71 (m, 2H, H-6b-D, H-6b-F), 1.38, (t, J = 7.1 Hz, 3H, SO3CH2CH3), 1.25 (t, J = 6.8 Hz, 
3H, SO3CH2CH3) ppm; 13C-NMR (101 MHz, CDCl3) δ 170.1, 169.8, 169.8, 169.3 (4 × CO), 139.1, 138.9, 
138.0, 137.9, 137.7, 135.3, 133.2, 132.9 (8C, Cq arom.), 128.4, 128.3, 128.2, 128.1, 128.0, 128.0, 127.9, 127.8, 
127.8, 127.6, 127.5, 127.1, 127.0, 126.4, 126.1, 125.8, 125.6 (32C, arom.), 101.1 (C-1-H), 98.0 (C-1-E), 97.8 
(C-1-F), 97.4 (C-1-G), 96.8 (C-1-D), 83.2 (C-4-D), 82.3 (C-3-D), 82.1 (C-4-F), 81.9 (C-2-D), 80.0 (C-2-F), 
79.7 (C-2-H), 79.6 (C-4-G), 79.4 (C-3-F), 76.0 (C-3-G), 75.1 (C-5-E), 74.7, 74.3, 73.6, 73.4, 73.2, 73.2,  
(6 × ArCH2), 74.5 (C-3-E), 74.5 (C-4-H), 74.4 (C-4-E), 74.0 (C-3-H), 72.5 (C-2-E), 70.0 (C-5-H), 69.2 (C-5-
D), 68.9 (C-5-F), 68.3 (C-6-H), 68.2 (C-5-G), 67.7 (C-6-E), 67.3 (C-2-G), 66.2, 65.8 (2 × SO3CH2CH3), 60.5, 
60.5, 58.9, 58.1, 55.1, 51.7 (6 × OCH3), 46.6 (C-7-D), 46.4 (C-7-F), 26.0 (C-6-D), 25.7 (C-6-F), 21.0, 20.8, 
20.5 (3 × COCH3), 15.0, 15.0 (2 × SO3CH2CH3) ppm; MALDI-TOF MS: m/z 1877.77 [M + Na]+ (Calcd. 
1877.68); Anal. Calcd. for C94H118O34S2 (1854.69): C, 60.83; H, 6.41; O, 29.31; S, 3.46. Found: C, 60.69; H, 
6.35; S, 3.41. 
Methyl [2,3,4-tri-O-methyl-6-deoxy-6-C-(ethylsulfonatomethyl)-α-D-glucopyranosyl]-(1→4)-[2,3-di-O-acetyl-6-
O-(2-naphthyl)methyl-β-D-glucopyranosyl]-(1→4)-[2,3,6-tri-O-benzyl-α-D-glucopyranosyl]-(1→4)-[methyl 
(2-O-acetyl-3-O-methyl-α-L-idopyranosyl)uronate]-(1→4)-2,3-di-O-benzyl-6-deoxy-6-C-(ethylsulfonatomethyl)-
α-D-glucopyranoside (7). To a solution of acceptor 21 (720 mg, 0.62 mmol) and donor 23 (752 mg, 0.93 
mmol) in dry CH2Cl2 (20 mL) 4 Å molecular sieves (0.50 g) were added. The stirred mixture was 
cooled to −50 °C under argon and activated by method B. The reaction mixture was allowed to warm 
up to −20 °C for 3 h. The crude product was purified by column chromatography (65:35 n-
hexane/EtOAc) to give 7 (726 mg, 63%) as a colourless syrup; Rf = 0.21 (1:1 n-hexane/EtOAc); [α]D 
+32.21 (c 0.14, CHCl3); 1H-NMR (400 MHz, CDCl3) δ 7.83–7.71 (m, 3H, arom.), 7.62 (s, 1H, arom.), 7.44 
(m, 2H, arom.), 7.41–7.12 (m, 26H, arom.), 5.21 (d, J = 2.3 Hz, 1H, H-1-G), 5.10–4.99 (m, 1H, H-3-E, 
ArCH2), 4.96–4.76 (m, 6H, H-1-D, H-2-G, H-2-E, H-1-F, 2 × ArCH2), 4.75–4.63 (m, 5H, H-5-G, 4 × 
ArCH2), 4.60–4.38 (m, 7H, H-1-E, H-1-H, 5 × ArCH2), 4.29 (q, J = 7.1 Hz, 2H, SO3CH2CH3), 4.06 (q, J = 
7.1 Hz, 2H, SO3CH2CH3), 3.95 (t, J = 9.4 Hz, 1H, H-4-H), 3.91–3.67 (m, 8H, H-4-G, H-4-E, H-6a-E, H-5-
H, H-3-H, H-3-F, H-6a-F, H-5-F), 3.67–3.25 (m, 9H, H-3-G, H-6b-F, H-6b-E, H-4-F, H-5-D, H-2-H, H-2-
F, H-3-D, H-7-H), 3.57, 3.53, 3.43, 3.41, 3.33 (5s, 15H, 5 × OCH3), 3.23–3.04 (m, 3H, H-5-E, H-7a-D, H-
7a-H), 2.97–2.87 (m, 2H, H-2-D, H-7b-D), 2.69 (t, J = 9.2 Hz, 1H, H-4-D), 2.44–2.30 (m, 1H, H-6a-H), 2.30–
2.14 (m, 1H, H-6a-D), 2.02, 1.96, 1.95 (3s, 9H, 3 × COCH3), 2.06–1.74 (m, 2H, H-6b-D, H-6b-H), 1.40 (t, J 
= 7.1 Hz, 3H, SO3CH2CH3), 1.23 (t, J = 7.4 Hz, 3H, SO3CH2CH3) ppm. 13C-NMR (101 MHz, CDCl3) δ 
170.3, 170.0, 169.7, 169.6 (4 × CO), 139.4, 139.0, 138.3, 138.1, 137.6, 135.8, 133.4, 133.0 (8C, Cq arom.), 
128.8, 128.6, 128.5, 128.4, 128.4, 128.2, 128.2, 128.1, 128.0, 127.9, 127.8, 127.6, 127.3, 126.4, 126.1, 125.9, 
125.8 (32C, arom.), 99.8 (C-1-E), 99.6 (C-1-F), 98.0 (C-1-H), 97.8 (C-1-G), 96.9 (C-1-D), 83.5 (C-4-D), 82.7 
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(C-3-D), 82.2 (C-2-D), 80.3 (C-4-F), 79.7 (C-3-H), 79.4 (C-3-F), 79.3 (C-2-F), 78.6 (C-2-H), 76.7 (C-4-H), 
76.5 (C-3-G), 75.3 (C-5-E), 74.9 (C-4-G), 74.9 (C-3-E), 74.9 (C-4-E), 72.5 (C-2-E), 71.1 (C-5-F), 69.5 (C-5-
D), 69.3 (C-5-G), 68.2 (C-5-H), 68.2 (C-2-G), 75.3, 75.1, 73.9, 73.7, 73.6, 73.6 (6 × ArCH2), 68.1 (C-6-E), 
67.4 (C-6-F), 66.3, 66.1 (2 × SO3CH2CH3), 60.8, 60.8, 59.2, 58.8, 55.6, 52.0 (6 × OCH3), 46.8, 46.8 (C-7-D, 
C-7-H), 26.2 (C-6-D), 26.0 (C-6-H), 21.1, 21.0, 20.8 (3 × COCH3), 15.2, 15.1 (2 × SO3CH2CH3) ppm; 
MALDI-TOF MS: m/z 1877.77 [M + Na]+ (Calcd. 1877.68); Anal. Calcd. for C94H118O34S2 (1854.69): C, 
60.83; H, 6.41; O, 29.31; S, 3.46. Found: C, 60.90; H, 6.44; S, 3.51. 
Methyl [2,3,4-tri-O-methyl-6-deoxy-6-C-(ethylsulfonatomethyl)-α-D-glucopyranosyl]-(1→4)-[2,3-di-O-acetyl- 
6-O-6-O-(2-naphthyl)methyl-β-D-glucopyranosyl]-(1→4)-[2,3,6-tri-O-benzyl-α-D-glucopyranosyl]-(1→4)-
[methyl-(2-O-acetyl-3-O-methyl-α-L-idopyranosyl)uronate]-(1→4)-(2,3,6-tri-O-benzyl-α-D-glucopyranoside) (8). 
To a solution of acceptor 22 (1.18 g, 1.03 mmol) and donor 23 (1.25 g, 1.55 mmol) in dry CH2Cl2 (40 
mL), 4 Å molecular sieves (1 g) were added. The stirred mixture was cooled to −50 °C under argon 
and activated by method C. The reaction mixture was allowed to warm up to 0 °C for 4 h. The crude 
product was purified by column chromatography (6:4 n-hexane/EtOAc) to give 8 (1.29 g, 68%) as a 
colourless syrup; Rf = 0.51 (94:6 CH2Cl2/acetone); [α]D +24.44 (c 0.05, CHCl3); 1H-NMR (400 MHz, 
CDCl3) δ 7.86–7.71 (m, 3H, arom.), 7.62 (s, 1H, arom.), 7.44 (m, 2H, arom.), 7.40–7.11 (m, 31H, arom.), 
5.15 (d, J = 2.7 Hz, 1H, H-1-G), 5.05 (m, 2H, H-3-E, ArCH2), 4.95–4.75 (m, 7H, H-1-D, H-2-E, H-1-F, H-
2-G, 3 × ArCH2), 4.74–4.65 (m, 5H, H-5-G, 4 × ArCH2), 4.62–4.46 (m, 6H, H-1-H, 5 × ArCH2), 4.45–4.40 
(m, 2H, H-1-E, ArCH2), 4.05 (q, J = 7.1 Hz, 2H, SO3CH2CH3), 3.95 (t, J = 9.4 Hz, 1H, H-4-F), 3.91–3.45 
(m, 16H, H-4-G, H-4-H, H-4-E, H-3-H, H-5-F, H-6a,b-H, H-3-F, H-5-H, H-3-G, H-6a,b-E, H-6a,b-F, H-5-
D, H-2-H), 3.57, 3.53, 3.41, 3.35, 3.34, 3.32 (6s, 18H, 6 × OCH3), 3.44–3.27 (m, 4H, H-2-F, H-3-D, H-5-E, 
H-7a-D), 2.97–2.85 (m, 2H, H-2-D, H-7b-D), 2.69 (t, J = 9.2 Hz, 1H, H-4-D), 2.26–2.15 (m, 1H, H-6a-D), 
2.01, 1.91, 1.89 (3s, 9H, 3 × COCH3), 1.87–1.75 (m, 1H, H-6b-D), 1.23 (t, J = 7.1 Hz, 3H, SO3CH2CH3) 
ppm; 13C-NMR (91 MHz, CDCl3) δ 170.2, 170.0, 169.7, 169.6 (4 × CO), 139.5, 139.2, 138.3, 138.3, 138.1, 
137.7, 135.8, 133.4, 133.0 (9C, Cq arom.), 128.8, 128.5, 128.4, 128.2, 128.2, 128.0, 127.9, 127.8, 127.8, 127.6, 
127.5, 127.3, 127.1, 126.4, 126.1, 125.9, 125.8 (37C, arom.), 99.8 (C-1-E), 99.7 (C-1-F), 98.1 (C-1-H), 97.8 
(C-1-G), 96.9 (C-1-D), 83.6 (C-4-D), 82.7 (C-3-D), 82.2 (C-2-D), 80.1 (C-2-H), 79.9 (C-3-H), 79.8 (C-3-F), 
79.3 (C-2-F), 76.8 (C-3-G), 76.5 (C-4-F), 75.3 (C-5-E), 75.1 (C-3-E), 75.1 (C-4-E), 74.9 (C-4-G), 74.9 (C-4-
H), 75.1, 75.1, 75.1, 73.8, 73.6, 73.5, 73.5 (7 × ArCH2), 72.5 (C-2-E), 71.0 (C-5-F), 70.2 (C-5-H), 69.5 (C-5-
D), 69.2 (C-5-G), 68.5 (C-2-G), 68.3 (C-6-F), 68.3 (C-6-E), 67.4 (C-6-H), 66.0 (SO3CH2CH3), 60.8, 60.8, 
59.2, 58.8, 55.3, 51.8 (6 × OCH3), 46.8 (C-7-D), 26.2 (C-6-D), 21.1, 21.1, 20.8 (3 × COCH3), 15.1 
(SO3CH2CH3) ppm; MALDI-TOF MS: m/z 1862.75 [M + Na]+ (Calcd. 1863.02); Anal. Calcd. for 
C98H118O32S (1840.03): C, 63.97; H, 6.46; O, 27.82; S, 1.74. Found: C, 64.03; H, 6.49; S, 1.68. 
Methyl-[6-O-benzyl-2,3,4-tri-O-methyl-α-D-glucopyranosyl]-(1→4)-[2,3-di-O-acetyl-6-O-(2-naphthyl)methyl- 
β-D-glucopyranosyl]-(1→4)-[2,3-di-O-benzyl-6-deoxy-6-C-(ethylsulfonatomethyl)-α-D-glucopyranosyl]- 
(1→4)-[methyl-(2-O-acetyl-3-O-methyl-α-L-idopyranosyl)uronate]-(1→4)-(2,3,6-tri-O-benzyl-α-D-glucopyranoside) 
(9). To a solution of acceptor 20 (1.20 g, 1.04 mmol) and donor 24 (1.23 g, 1.55 mmol) in dry CH2Cl2 
(40 mL), 4 Å molecular sieves (1 g) were added. The stirred mixture was cooled to −35 °C under argon 
and activated by method C. The reaction mixture was allowed to warm up to −20 °C for 4 h. The 
crude product was purified twice by column chromatography (I. 6:4 n-hexane/EtOAc II. 96:4 
CH2Cl2/EtOAc) to give 9 (1.20 g, 63%) as colourless; Rf = 0.33 (1:1 n-hexane/EtOAc); [α]D +26.28 (c 0.06, 
CHCl3); 1H-NMR (400 MHz, CDCl3) δ 7.84–7.71 (m, 3H, arom.), 7.63 (s, 1H, arom.), 7.50–7.41 (m, 2H, 
arom.), 7.38–7.11 (m, 31H, arom), 5.22 (t, J = 9.3 Hz, 1H, H-3-E), 5.12–5.03 (m, 2H, H-1-G, H-1-D), 4.95 
(t, J = 12.3 Hz, 2H, 2 × ArCH2), 4.89–4.48 (m, 15H, H-2-E, H-5-G, H-2-G, H-1-E, H-1-F, H-1-H, 9 × 
ArCH2), 4.40 (d, J = 10.9 Hz, 2H, 2 × ArCH2), 4.26 (m, 3H, SO3CH2CH3, ArCH2), 3.98–3.43 (m, 14H, H-
4-E, H-4-H, H-4-G, H-3-F, H-3-H, H-5-F, H-5-H, H-6a,b-H, H-3-G, H-6a,b-E, H-2-H, H-5-D), 3.55, 3.39, 
3.39, 3.38, 3.34, 3.30 (6s, 18H, 6 × OCH3) 3.43–2.99 (m, 9H, H-6a,b-D, H-4-F, H-5-E, H-2-F, H-3-D, H-7a,b-
F, H-4-D, H-2-D), 2.31–2.20 (m, 1H, H-6a-F), 2.04, 1.99, 1.93 (3s, 9H, 3 × OCH3), 1.85–1.70 (m, 1H, H-6b-
F), 1.39 (t, J = 7.1 Hz, 3H, SO3CH2CH3) ppm; 13C-NMR (91 MHz, CDCl3) δ 170.3, 170.0, 169.9, 169.5 (4 
× CO), 139.2, 139.1, 138.2, 138.1, 138.1, 137.9, 136.0, 133.3, 133.0 (9C, Cq arom.), 128.5, 128.5, 128.4, 128.4, 
128.3, 128.2, 128.1, 128.0, 127.8, 127.7, 127.3, 127.2, 126.7, 126.2, 126.1, 125.9, 125.6 (37C, arom.), 101.1 
(C-1-E), 98.3 (C-1-F), 98.1 (C-2-H), 97.9 (C-1-D), 97.6 (C-1-G), 83.2 (C-3-D), 82.1 (C-4-F), 81.8 (C-2-D), 80.2 
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(C-2-H), 79.9 (C-3-H), 79.8 (C-2-F), 79.5 (C-3-F), 79.3 (C-4-D), 76.1 (C-3-G), 75.1 (C-5-E), 75.0 (C-3-E), 74.8 
(C-4-H), 74.5 (C-4-E), 74.2 (C-4-G), 74.9, 74.6, 73.8, 73.5, 73.4, 73.4, 73.4 (7 × ArCH2), 72.9 (C-2-E), 71.2 
(C-5-D), 70.2 (C-5-F), 69.1 (C-5-H), 68.6 (C-6-E), 68.5 (C-6-H), 68.4 (C-5-G), 68.3 (C-6-D), 67.4 (C-2-G), 
66.3 (SO3CH2CH3), 60.7, 60.4, 59.4, 58.2, 55.3, 51.9 (6 × OCH3), 46.6 (C-7-F), 25.9 (C-6-F), 21.2, 21.0, 20.7 
(3 × COCH3), 15.2 (SO3CH2CH3) ppm; MALDI-TOF MS: m/z 1862.74 [M + Na]+ (Calcd. 1863.02); Anal. 
Calcd. for C98H118O32S (1840.03): C, 63.97; H, 6.46; O, 27.82; S, 1.74. Found: C, 63.95; H, 6.51; S, 1.78. 
Methyl [6-O-benzyl-2,3,4-tri-O-methyl-α-D-glucopyranosyl]-(1→4)-[2,3-di-O-acetyl-6-O-(2-naphthyl)methyl- 
β-D-glucopyranosyl]-(1→4)-[2,3,6-tri-O-benzyl-α-D-glucopyranosyl]-(1→4)-[methyl-(2-O-acetyl-3-O-methyl-
α-L-idopyranosyl)uronate]-(1→4)-2,3-di-O-benzyl-6-deoxy-6-C-(ethylsulfonatomethyl)-α-D-glucopyranoside 
(10). To a solution of acceptor 21. (720 mg, 0.62 mmol) and donor 24 (737 mg, 0.93 mmol) in dry CH2Cl2 
(20 mL), 4 Å molecular sieves (0.50 g) were added. The stirred mixture was cooled to −40 °C under 
argon and activated by method C. The reaction mixture was allowed to warm up to −10 °C for 90 
min. The crude product was purified twice by column chromatography (I. 9:1 CH2Cl2/EtOAc II. 6:4 
n-hexane/EtOAc) to give 10 (825 mg, 72%) as a colourless syrup; Rf = 0.31 (1:1 n-hexane/EtOAc); [α]D 
+35.45 (c 0.05, CHCl3); 1H-NMR (400 MHz, CDCl3) δ 7.82–7.69 (m, 3H, arom.), 7.62 (s, 1H, arom.), 7.48–
7.09 (m, 30H, arom.), 5.21 (d, J = 5.0 Hz, 1H, H-1-G), 5.12–5.03 (m, 3H, H-3-E, H-1-D, ArCH2), 4.92–
4.76 (m, 5H, H-2-E, H-1-F, H-2-G, 2 × ArCH2), 4.75–4.61 (m, 5H, H-5-G, 4 × ArCH2), 4.59–4.51 (m, 3H, 
3 × ArCH2), 4.49–4.37 (m, 5H, H-1-E, H-1-H, 3 × ArCH2), 4.34–4.25 (m, 3H, SO3CH2CH3, ArCH2), 4.01–3.84 
(m, 3H, H-4-H, H-4-E, H-4-G), 3.83–3.67 (m, 7H, H-3-H, H-5-F, H-6a-F, H-6a,b-E, H-5-H, H-3-F), 3.66–
3.52 (m, 3H, H-3-G, H-5-D, H-6b-F), 3.50–3.26 (m, 7H, H-6a,b-D, H-2-H, H-4-F, H-3-D, H-2-F, H-7a-H), 
3.59, 3.44, 3.42, 3.41, 3.33, 3.32 (6s, 18H, 6 × OCH3), 3.26–3.02 (m, 4H, H-5-E, H-4-D, H-7a-H, H-2-D), 
2.42–2.32 (m, 1H, H-6a-H), 2.01, 1.96, 1.94 (3s, 9H, 3 × COCH3),1.98–1.93 (m, 1H, H-7b-H) 1.39 (t, J = 
12.7 Hz, 3H, SO3CH2CH3) ppm; 13C-NMR (101 MHz, CDCl3) δ 170.3, 170.0, 169.7, 169.6 (4 × CO), 139.4, 
139.0, 138.4, 138.1, 138.1, 137.7, 136.2, 133.4, 133.0 (9C, Cq arom.), 128.8, 128.6, 128.4, 128.4, 128.3, 128.2, 
128.1, 128.0, 127.8, 127.7, 127.6, 127.3, 127.2, 126.0, 125.9, 125.7 (37C, arom.), 99.8 (C-1-E), 99.6 (C-1-F), 
98.0 (C-1-H), 97.9 (C-1-G), 97.9 (C-1-D), 83.3 (C-3-D), 81.9 (C-2-D), 80.3 (C-4-F), 79.8 (C-5-H), 79.8 (C-
3-F), 79.4 (C-4-D), 79.4 (C-3-H), 79.2 (C-2-F), 78.6 (C-2-H), 76.7 (C-3-G), 76.5 (C-4-H), 75.1 (C-4-G), 75.1 
(C-4-E), 75.1 (C-5-E) 74.9 (C-3-E), 75.3, 75.1, 73.9, 73.7, 73.6, 73.4, 73.4 (7 × ArCH2), 72.7 (C-2-E), 71.4 
(C-5-D), 71.1 (C-5-F), 69.3 (C-5-G), 68.9(C-6-E), 68.6 (C-6-D), 68.2 (C-2-G), 67.4 (C-6-F), 66.2 
(SO3CH2CH3), 60.8, 60.5, 59.3, 58.8, 55.6, 51.9 (6 × OCH3), 46.8 (C-7-H), 26.1 (C-6-H), 21.1, 21.0, 20.8 (3 
× COCH3), 15.2 (SO3CH2CH3) ppm; ESI-MS: m/z 1862.75 [M + Na]+ (Calcd. 1863.02); Anal. Calcd. for 
C98H118O32S (1838,73): C, 63.97; H, 6.46; O, 27.82; S, 1.74. Found: C, 64.07; H, 6.53; S, 1.82. 
Methyl [6-O-benzyl-2,3,4-tri-O-methyl-α-D-glucopyranosyl]-(1→4)-[6-O-(2-naphthyl)-methyl-β-D-
glucopyranosyl]-(1→4)-[sodium (2,3-di-O-benzyl-6-deoxy-6-C-sulfonato-methyl-α-D-glucopyranosyl)]-(1→4)- 
[methyl (3-O-methyl-α-L-idopyranosyl)uronate]-(1→4)-(2,3,6-tri-O-benzyl-α-D-glucopyranoside) (25). 
NaOMe (36 mg) was added to the solution of compound 9 (1.22, 0.66 mmol) in MeOH (35 mL) at 
room temperature and stirred for 24 h. The reaction mixture was quenched by the addition of acetic 
acid (1–2 drops) and the solution was concentrated. Then, NaI (149 mg, 0.99 mmol) was added to the 
solution of crude product in acetone (40 mL) and the mixture was stirred at room temperature for 24 
h. The mixture was concentrated and purified by gel chromatography (Sephadex LH-20, MeOH) to 
give 25 (919 mg, 81% for two steps) as a colourless syrup; Rf = 0.28 (95:5 CH2Cl2/MeOH); [α]D +33.7 (c 0.11, 
CHCl3); 1H-NMR (CDCl3, 400 MHz): δ (ppm) 7.79–7.07 (m, 37H, arom.), 5.34–4.21 (m, 19H, 7 × ArCH2, 5 × 
H-1), 3.98–2.87 (m, 49H, 20 × skeleton protons, 6 × OCH3, 3 × H-6a,b, H-7a,b, 3 × OH), 2.43–2.38 (m, 1H, 
H-6a-F), 2.13–2.03 (m, 1H, H-6b-F); 13C-NMR (CDCl3, 100 MHz): δ (ppm) 171.3 (CO), 140.7, 140.1, 139.4, 
139.3, 138.9, 137.4, 134.6, 134.3 (9 × Cq arom.), 129.4–126.8 (37C, arom.), 104.3, 102.2, 99.5, 98.9, 96.0  
(5 × C-1), 84.6, 83.5, 81.7, 81.3, 81.2, 80.7, 80.3, 79.7, 78.0, 76.3, 75.9, 75.6, 72.6, 72.3, 71.6, 70.8, 69.2, 67.9 
(20C, skeleton carbons), 75.7, 74.9, 74.4, 74.2, 73.9 (7 × ArCH2), 69.8 (3 × C-6) 60.9, 60.8, 59.8, 58.5 (4 × 
OCH3), 55.5 (C-1-OCH3), 52.9 (COOCH3), 48.2 (C-7-F), 27.6 (C-6-F); MALDI-TOF MS: m/z 1729.72 [M + Na]+ 
(Calcd. 1729.64). Anal. Calcd. for C90H107NaO29S (1707.85): C, 63.29; H, 6.31; S, 1.88. Found: C, 63.37; 
H, 6.40; S, 1.97. 
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Methyl [6-O-benzyl-2,3,4-tri-O-methyl-α-D-glucopyranosyl]-(1→4)-[2,3-di-O-methyl-6-O-(2-naphthyl)methyl- 
β-D-glucopyranosyl]-(1→4)-[sodium (2,3-di-O-benzyl-6-deoxy-6-C-sulfonatomethyl-α-D-glucopyranosyl)]-(1→4)- 
[methyl (2,3-di-O-methyl-α-L-idopyranosyl)uronate]-(1→4)-(2,3,6-tri-O-benzyl-α-D-glucopyranoside) (26). An 
amount of 60 m/m% NaH (68 mg, 1.68 mmol) was added to the solution of compound 25 (798 mg, 
0.467 mmol) in dry N,N-dimethylmethanamide (DMF) (15 mL) at 0 °C. After 30 min of stirring at 
room temperature, MeI (105 μL, 1.68 mmol) was added to the reaction mixture and it was stirred for 
4 h. The reaction mixture was quenched by the addition of MeOH (4–5 drops). The solution was 
concentrated and the crude product was purified by gel chromatography (Sephadex LH-20 in MeOH) 
to give 26 (550 mg, 67%) as a colourless syrup; Rf = 0.58 (9:1 CH2Cl2/MeOH); [α]D +49.4 (c 0.26, CHCl3); 
1H-NMR (CDCl3, 400 MHz): δ (ppm) 7.79–7.12 (m, 37H, arom.), 5.58 (d, J = 3.6 Hz, 1H), 5.21 (d, J = 5.6 
Hz, 1H), 5.00–4.33 (m, 17H), 3.86–2.98 (m, 55H, 20 × skeleton protons, 9 × OCH3, 3 × H6a,b, H-7a,b), 2.48–
2.39 (m, 1H, H-6a-F), 2.02–2.01 (m, 1H, H-6b-F); 13C-NMR (CDCl3, 100 MHz): δ (ppm) 169.8 (CO), 139.3, 
138.9, 138.3, 138.2, 138.1, 138.0, 136.1, 133.2, 132.8 (9 × Cq arom.), 128.3–125.6 (37C, arom.), 103.0, 100.1, 
99.7, 98.0, 96.0 (5 × C-1), 86.3, 84.8, 83.3, 81.6, 80.7, 80.2, 79.8, 79.6, 79.5, 79.1, 78.3, 76.4, 74.3, 74.2, 72.0, 
71.5, 70.7, 70.2, 69.9, 69.6 (20C, skeleton carbons), 75.2, 75.1, 74.6, 73.5, 73.3, 73.2, 72.9 (7 × ArCH2), 69.1, 
68.3, 68.0 (3 × C-6), 60.6, 60.4, 60.2, 59.7, 59.6, 59.4, 59.3 (7 × OCH3), 55.2 (C-1-OCH3), 51.7 (COOCH3), 
46.8 (C-7-F), 26.4 (C-6-F); MALDI-TOF MS: m/z 1771.76 [M + Na]+ (Calcd. 1771.69). Anal. Calcd. for 
C93H113NaO29S (1749.93): C, 63.83; H, 6.51; S, 1.83. Found: C, 63.92; H, 7.03; S, 2.01. 
Methyl [6-O-benzyl-2,3,4-tri-O-methyl-α-D-glucopyranosyl]-(1→4)-[2,3-di-O-methyl-β-D-glucopyranosyl]- 
(1→4)-[sodium (2,3-di-O-benzyl-6-deoxy-6-C-sulfonatomethyl-α-D-glucopyranosyl)]-(1→4)-[methyl (2,3-di-
O-methyl-α-L-idopyranosyl)uronate]-(1→4)-(2,3,6-tri-O-benzyl-α-D-glucopyranoside) (27). Compound 26 
(550 mg, 0.314 mmol) was converted to 27 according to general method D. The crude product was 
purified by column chromatography (9:1 CH2Cl2/MeOH) to give 27 (404 mg, 80%) as a colourless 
syrup; Rf = 0.52 (9:1 CH2Cl2/MeOH); [α]D +24.2 (c 0.06, CHCl3); 1H-NMR (CDCl3, 400 MHz): δ (ppm) 
7.35–7.24 (m, 30H, arom.), 5.50 (s, 1H), 5.18 (s, 2H), 4.82–4.57 (m, 15H), 3.94–3.15 (m, 55H, 20 skeleton 
protons, 9 × OCH3, 3 × H-6a,b, H-7a,b), 2.52–2.41 (m, 1H, H-6a-F), 2.08–1.99 (m, 1H, H-6b-F); 13C-NMR 
(CDCl3, 100 MHz): δ (ppm) 171.7 (CO), 140.3–139.5 (6 × Cq arom.), 129.5–128.4 (30C, arom.), 103.5, 
100.6, 99.0, 97.8, 97.0 (5 × C-1), 87.6, 86.4, 84.4, 83.0, 81.7, 81.4, 80.9, 80.6, 80.5, 80.4, 79.7, 76.8, 76.6 (20C, 
skeleton carbons), 76.6, 76.0, 74.9, 74.5, 74.1 (6 × ArCH2), 70.0, 69.7, 62.8 (3 × C-6), 61.0, 60.8, 60.6, 59.9, 
59.7 (7 × OCH3), 55.6 (C-1-OCH3), 52.6 (COOCH3), 49.0 (C-7-F), 27.8 (C-6-F); MALDI-TOF MS: m/z 
1631.77 [M + Na]+ (Calcd. 1631.63). Anal. Calcd. for C82H105NaO29S (1609.75): C, 61.18; H, 6.57; S, 1.99. 
Found: C, 61.24; H, 6.59; S, 2.08. 
Methyl-(6-O-benzyl-2,3,4-tri-O-methyl-α-D-glucopyranosyl)-(1→4)-[sodium (2,3-di-O-methyl-β-D-glucopyranosyl) 
uronate]-(1→4)-(sodium (2,3-di-O-benzyl-6-deoxy-6-C-sulfonatomethyl-α-D-glucopyranosyl)-(1→4)-[methyl (2,3-
di-O-methyl-α-L-idopyranosyl)uronate]-(1→4)-(2,3,6-tri-O-benzyl-α-D-glucopyranoside) (28). To a vigorously 
stirred solution of 27 (40 mg, 0.025 mmol) in CH2Cl2 (2.0 mL) and H2O (1.0 mL), TEMPO (0.8 mg, 
0.005 mmol, 0.2 equiv.) and BAIB (32 mg, 0.099 mmol, 4 equiv.) were added. After 24 h, the TLC (9:1 
CH2Cl2/MeOH) indicated moderate conversion of the starting material. Another portion of BAIB (32 
mg, 0.099 mmol, 4 equiv.) were added and the stirring was continued for a further 24 h. The reaction 
mixture was quenched by the addition of 10% aq Na2S2O3 solution (4 mL). The mixture was then 
extracted twice with EtOAc (8 mL), and the combined organic layers were dried, and concentrated. The 
residue was purified by column chromatography (9:1 CH2Cl2/MeOH) to give a colourless syrup (31 mg). 
The mass spectrum contained peaks corresponding to 28 and its partially debenzylated derivatives; this 
mixture was used in the subsequent reaction without further purification. MALDI-TOF MS for 
C82H102Na2O30S (1644.60): m/z 1667.65 [M + Na]+ (Calcd. 1667.59); 1379.56 [M + Na (−3Bn)]+ (Calcd. 
1379.45); 1487.56 [M + Na (−2Bn)]+ (Calcd. 1487.49). 
Nona sodium [methyl (2,3,4-tri-O-methyl-6-O-sulfonato-α-D-glucopyranosyl)-(1→4)-[sodium (2,3-di-O-
methyl-β-D-glucopyranosyl)uronate]-(1→4)-[sodium (2,3-di-O-sulfonato-6-deoxy-6-C-sulfonatomethyl-α-D-
glucopyranosyl)-(1→4)-[sodium (2,3-di-O-methyl-α-L-idopyranosyl)uronate]-(1→4)-2,3,6-tri-O-sulfonato-
α-D-glucopyranoside (29). An amount of 0.5 M NaOH solution (0.30 mL) was added to the solution of 
28 (30 mg) in a mixture of THF (0.30 mL) and MeOH (0.30 mL) and stirred at room temperature for 
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24 h. The reaction was quenched by the addition of 1 N HCl solution (1 drop) and the mixture was 
concentrated. The crude product was converted to sodium salt by ion exchange resin (Dowex, MeOH) to 
give a colourless syrup (28 mg). The syrupy residue was dissolved in 96% EtOH (3.0 mL) and 10% 
Pd/C (10 mg) and acetic acid (100 μL) were added. The mixture was stirred at room temperature for 
24 h under a 10 bar H2 atmosphere. The mixture was diluted with MeOH, the catalyst was filtered off 
through a pad of Celite and the filtrate was concentrated. The crude product was purified by column 
chromatography (7:6:1 CH2Cl2/MeOH/H2O, Rf = 0.13) and gel chromatography (Sephadex G-25, H2O) 
to give the corresponding pentaol (9 mg) which was characterized by MALDI MS. (MALDI-TOF MS 
for C39H63Na3O30S (1112.28): m/z 1091.39 [M − Na + 2H]+ (Calcd. 1091.31), 1113.39 [M + H]+ (Calcd. 
1113.29), 1135.42 [M + Na]+ (Calcd. 1135.27). To the solution of the pentaol derivative (9 mg) in dry 
DMF (0.6 mL), SO3·Et3N complex (44 mg, 0.040 mmol) was added and the reaction mixture was stirred 
at 50 °C for 48 h. The reaction was quenched with satd. aq. NaHCO3 (21 mg, 0.24 mmol). The solution 
was concentrated. The crude product was treated with Dowex ion-exchange resin (Na+ form), and 
then purified by Sephadex G-25 column chromatography eluting with H2O to give 29 (7 mg, 17% 
from 27) as a white solid. ESI-MS for C39H57Na9O48S7 (1723.91): m/z 795.110 [M − 6Na + 4H]2− (Calcd. 
795.00); 522.451 [M − 7Na + 4H]3− (Calcd.: 522.34). 
Methyl [2,3,4-tri-O-methyl-6-deoxy-6-C-(ethylsulfonatomethyl)-α-D-glucopyranosyl]-(1→4)-[2,3-di-O-acetyl-β-
D-glucopyranosyl]-(1→4)-[2,3-di-O-benzyl-6-deoxy-6-C-(ethylsulfonatomethyl)-α-D-glucopyranosyl]-(1→4)-
[methyl (2-O-acetyl-3-O-methyl-α-L-idopyranosyl)uronate]-(1→4)-(2,3,6-tri-O-benzyl-α-D-glucopyranoside) 
(30). Compound 6 (975 mg, 0.53 mmol) was converted to 30 according to general method D. The 
crude product was purified by column chromatography (94:6 CH2Cl2/acetone) to give compound 30 
(612 mg, 68%) as a colourless syrup; Rf = 0.26 (93:7 CH2Cl2/acetone); [α]D +30.56 (c 0.10, CHCl3); 1H-
NMR (360 MHz, CDCl3) δ 7.45–7.17 (m, 25H, arom.), 5.23 (t, J = 9.3 Hz, 1H, H-3-E), 5.11 (s, 1H, H-1-
G), 5.00 (d, J = 3.6 Hz, 1H, H-1-D), 4.96–4.49 (m, 16H, H-2-E, H-5-G, H-2-G, H-1-E, H-1-H, H-1-F, 10 × 
PhCH2), 4.29 (q, J = 7.1, 1.2 Hz, 4H, 2 × SO3CH2CH3), 3.93–3.07 (m, 21H, skeleton protons), 3.55, 3.52, 
3.41, 3.41, 3.34, 3.31 (6s, 18H, 6 × OCH3), 3.01 (dd, J = 9.8, 3.6 Hz, 1H, H-2-D), 2.72 (t, J = 9.3 Hz, 1H, H-
4-D), 2.34–2.22 (m, 2H, H-6a-D, H-6a-F), 2.03, 2.01, 1.96 (3s, 9H, 3 × COCH3), 1.94–1.75 (m, 3H, H-6b-D, 
H-6b-F, OH), 1.41 (m, 6H, 2 × SO3CH2CH3) ppm; 13C-NMR (91 MHz, CDCl3) δ 170.2, 170.0, 169.6, 169.6 
(4 × CO), 139.1, 139.0, 138.1, 138.1, 137.9 (5C, Cq arom.), 128.6, 128.6, 128.4, 128.4, 128.2, 128.1, 127.9, 
127.8, 127.6, 127.3, 127.1, 126.1 (25C, arom.), 100.9, 98.4, 98.0, 97.6, 96.8 (5 × C-1), 83.8, 82.8, 82.1, 81.7, 
80.2, 79.8, 79.4, 79.1, 76.1, 75.3, 74.8, 74.2, 72.6, 72.2, 70.2, 69.6, 69.2, 68.4, 67.5 (20C, skeleton carbons),  
74.6, 73.9, 73.4, 73.4, 73.4 (5 × PhCH2), 68.4, 60.6 (C-6-H, C-6-E), 66.3, 66.1 (2 × SO3CH2CH3), 60.8, 60.7, 
59.5, 58.2, 55.3, 51.8 (6 × OCH3), 46.8, 46.6 (C-7-D, C-7-F), 26.4, 25.5 (C-6-D, C-6-F), 21.1, 21.0, 20.6 (3 × 
COCH3), 15.2, 15.2 (2 × SO3CH2CH3) ppm; MALDI-TOF MS: m/z 1737.62 [M + Na]+ (Calcd. 1737.62); 
Anal. Calcd. for C83H110O34S2 (1714.63): C, 58.10; H, 6.46; O, 31.70; S, 3.74. Found: C, 58.21; H, 6.41; S, 3.70. 
Methyl [2,3,4-tri-O-methyl-6-deoxy-6-C-(ethylsulfonatomethyl)-α-D-glucopyranosyl]-(1→4)-[sodium (2,3-
di-O-acetyl-β-D-glucopyranosyl)uronate]-(1→4)-[2,3-di-O-benzyl-6-deoxy-6-C-(ethylsulfonatomethyl)-α-D-
glucopyranosyl]-(1→4)-[methyl (2-O-acetyl-3-O-methyl-α-L-idopyranosyl)uronate]-(1→4)-(2,3,6-tri-O-
benzyl-α-D-glucopyranoside) (31). Compound 30 (2.4 g, 1.87 mmol) was converted to 31 according to 
general method A. The reaction mixture was stirred for 24 h. The crude product was purified by 
column chromatography (98:2 CH2Cl2/MeOH) to give 31 (528 mg, 80%) as a colourless syrup; Rf = 
0.50 (95:5 CH2Cl2/MeOH); [α]D +29.26 (c 0.11, CHCl3); 1H-NMR (360 MHz, CDCl3) δ 7.38–7.19 (m, 25H, 
arom.), 5.26–5.18 (m, 1H), 5.08 (s, 1H, H-1-G), 5.00 (d, J = 3.5 Hz, 1H, H-1-D), 4.96–4.49 (m, 16H, 10 × 
PhCH2, skeleton protons), 4.30, 4.28 (2q, 4H, 2 × SO3CH2CH3), 4.04 (t, J = 8.8 Hz, 1H), 3.93–3.77 (m, 4H, 
skeleton protons), 3.77–3.60 (m, 4H, skeleton protons), 3.59–3.18 (m, 8H skeleton protons), 3.56, 3.52, 
3.42, 3.39, 3.34, 3.30 (6s, 18H, 6 × OCH3), 3.16–3.05 (m, 1H, H-7b), 3.01 (dd, J = 9.8, 3.6 Hz, 1H, H-2-D), 
2.72 (t, J = 9.3 Hz, 1H, H-4-D), 2.33–2.17 (m, 2H, H-6a-D, H-6a-F), 2.03, 2.01, 1.95 (3s, 9H, 3 × COCH3), 
1.91–1.77 (m, 2H, H-6b-D, H-6b-F), 1.39, 1.38 (m, 6H, 2 × SO3CH2CH3) ppm; 13C-NMR (91 MHz, CDCl3) 
δ 170.4, 169.9, 169.5, 169.5, 169.0 (5 × CO), 139.1, 138.7, 138.1, 138.1, 137.8 (5C, Cq arom.), 128.6, 128.5, 
128.4, 128.2, 128.2, 128.1, 127.9, 127.8, 127.7, 127.6, 127.5, 127.3, 127.2 (25C, arom.), 100.8, 98.4, 98.0, 
97.6, 97.6 (5 × C-1), 83.8, 82.7, 81.9, 81.6, 80.2, 80.1, 79.8, 79.0, 76.2, 75.3, 74.7, 74.4, 74.4, 74.0, 72.4, 70.2, 
69.5, 69.1, 68.3, 67.4 (20C, skeleton carbons), 74.9, 74.8, 73.8, 73.4, 73.4 (5 × PhCH2), 68.5 (C-6-H), 66.6, 
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66.4 (2 × SO3CH2CH3), 60.7, 60.7, 59.5, 58.2, 55.3, 51.9 (6 × OCH3), 46.6, 46.5 (C-7-D, C-7-F), 26.0, 25.7 
(C-6-D, C-6-F), 21.1, 20.9, 20.6 (3 × COCH3), 15.2, 15.2 (2 × SO3CH2CH3) ppm; MALDI-TOF MS: m/z 
1773.53 [M + Na]+ (Calcd. 1773.58); Anal. Calcd. for C83H107O35S2 (1714.63): C, 58.10; H, 6.46; O, 31.70; 
S, 3.74. Found: C, 58.21; H, 6.41; S, 3.70. 
Methyl [2,3,4-tri-O-methyl-6-deoxy-6-C-(sulfonatomethyl)-α-D-glucopyranosyl]-(1→4)-[sodium (β-D-
glucopyranosyl)uronate]-(1→4)-[2,3-di-O-benzyl-6-deoxy-6-C-(sulfonatomethyl)-α-D-glucopyranosyl]-(1→4)- 
[methyl (3-O-methyl-α-L-idopyranosyl)uronate]-(1→4)-(2,3,6-tri-O-benzyl-α-D-glucopyranoside) (32). 
NaOMe (2 mg, 0.03 mmol) was added to the solution of compound 31 (500 mg, 0.29 mmol) and stirred 
at room temperature for 24 h. The mixture was quenched by the addition of acetic acid (1–2 drops) 
and then concentrated. The crude product was dissolved in acetone (20 mL) and NaI (128 mg, 0.86 
mmol) was added to the solution. The reaction mixture was stirred at room temperature for 24 h. The 
mixture was concentrated and the crude product was purified by gel chromatography (Sephadex 
LH-20, MeOH) to give 32 (386 mg, 84% for two steps) as a colourless syrup. Rf = 0.47 (7:3 
CH2Cl2/MeOH); [α]D +34.32 (c 1.66, CHCl3); 1H-NMR (360 MHz, CDCl3) δ 7.44–7.15 (m, 25H, arom.), 
5.51 (d, J = 3.5 Hz, 1H), 5.10 (s, 1H), 5.03 (d, J = 3.3 Hz, 1H), 5.02–4.50 (m, 14H, 5 × PhCH2, skeleton 
protons), 3.99–3.21 (m, 22H, skeleton protons), 3.57, 3.52, 3.52, 3.46, 3.36, 3.35 (6s, 18H, 6 × OCH3), 3.13 
(dd, J = 9.8, 3.6 Hz, 1H, H-2-D), 3.08–2.95 (m, 2H, H-7a-D, H-7a-F), 2.84–2.75 (m, 1H, H-4-D), 2.43–2.31 
(m, 1H, H-6a), 2.30–2.18 (m, 1H, H-6a), 2.11–1.78 (m, 2H, 2 × H-6b) ppm; 13C-NMR (91 MHz, CDCl3) δ 
177.8, 171.6 (2 × CO), 140.2, 140.1, 139.5, 139.4, 139.0 (5C, Cq arom.), 129.6, 129.3, 129.2, 129.1, 128.9, 
128.7, 128.4 (25C, arom.), 104.3, 102.3, 98.9, 98.2, 95.9 (5 × C-1), 85.1, 83.7, 81.8, 81.2, 80.8, 80.4, 79.3, 
78.4, 78.2, 76.2, 75.9, 75.7, 75.2, 73.6, 72.5, 71.7, 70.9, 70.7, 69.1, 67.8 (20C, skeleton carbons), 76.3, 76.1, 
75.0, 74.5, 74.0 (5 × PhCH2), 69.8 (C-6-H), 60.8, 60.6, 59.3, 59.2, 58.5, 55.5 (6 × OCH3), 28.3, 27.8 (C-6-D, 
C-6-F) ppm; MALDI-TOF MS: m/z 1635.50 [M + Na]+ (Calcd. 1635.45); Anal. Calcd. for C73H91Na3O32S2 
(1612.46): C, 54.34; H, 5.68; Na, 4.27; O, 31.73; S, 3.97. Found: C, 54.23; H, 5.66; S, 4.03. 
Methyl-[sodium 2,3,4-tri-O-methyl-6-deoxy-6-C-(sulfonatomethyl)-α-D-glucopyranosyl]-(1→4)-[sodium 
(2,3-di-O-methyl-β-D-glucopyranosyl)uronate]-(1→4)-[2,3-di-O-benzyl-6-deoxy-6-C-(sulfonatomethyl)-α-D-
glucopyranosyl]-(1→4)-[methyl (2,3-di-O-methyl-α-L-idopyranosyl)uronate]-(1→4)-2,3,6-tri-O-benzyl-α-D- 
glucopyranoside (33). An amount of 60 m/m% NaH (55 mg, 1.38 mmol) was added to the solution of 
compound 32 (370 mg, 0.23 mmol) in dry DMF (40 mL) at 0 °C. After 30 min of stirring at room 
temperature, MeI (64 μL, 1.04 mmol) was added to the reaction mixture and it was stirred for 4 h. 
The reaction mixture was quenched by the addition of MeOH and acetic acid (1–2 drops). The 
solution was concentrated and the crude product was purified by gel chromatography (Sephadex 
LH-20, MeOH) to give 33 (249 mg, 65%) as a colourless syrup; Rf = 0.53 (7:3 CH2Cl2/MeOH); [α]D +4.09 
(c 0.81, CHCl3); 1H-NMR (360 MHz, CDCl3) δ 7.49–7.10 (m, 25H, arom.), 5.15–4.51 (m, 17H, 5 × H-1, 
H-5-E, H-5-G, 10 × PhCH2), 4.00–3.24 (m, 20H, skeleton protons), 3.57, 3.55, 3.53, 3.49, 3.46, 3.43, 3.38, 
3.36, 3.35 (9s, 27H, 9 × OCH3), 3.11 (dd, J = 9.7, 3.6 Hz, 1H, H-2-D), 3.09–2.77 (m, 2H, 2 × H-7b), 2.56–
2.38 (m, 1H, H-6a), 2.30–2.17 (m, 1H, H-6a), 2.07–1.85 (m, 2H, 2 × H-6b) ppm; 13C-NMR (101 MHz, 
MeOD) δ 170.4, 170.0 (2 × CO), 139.3, 139.3, 138.5, 138.4, 138.4 (5C, Cq arom.), 128.8, 128.7, 128.6, 128.5, 
128.3, 128.3, 128.2, 128.1, 128.0, 127.9, 127.6 (25C, arom.), 100.1, 100.0, 98.4, 96.7, 96.0 (5 × C-1), 86.2, 
84.2, 83.8, 83.5, 82.7, 82.1, 81.7, 81.4, 80.3, 79.5, 79.2, 78.9, 76.5, 74.7, 74.3, 71.6, 71.4, 70.7, 70.1, 68.8 (20C, 
skeleton carbons), 75.7, 75.5, 75.2,73.8, 73.8 (5 × PhCH2), 73.9 (C-6-H), 60.9, 60.9, 60.1, 60.0, 59.8, 59.3, 
55.5, 53.0, 52.3, (9 × COCH3), 47.6, 47.5 (C-7-D, C-7-F), 27.5, 27.3 (C-6-D, C-6-F) ppm; MALDI-TOF MS: 
m/z 1655.53 [M + Na]+ (Calcd. 1655.52); Anal. Calcd. for C76H97Na3O32S2 (1654.51): C, 55.13; H, 5.91; Na, 
4.17; O, 30.92; S, 3.87. Found: C, 55.20; H, 5.97; S, 3.79. 
Methyl [2,3,4-tri-O-methyl-6-deoxy-6-C-sulfonatomethyl-α-D-glucopyranosyl]-(1→4)-[sodium (2,3-di-O-methyl- 
β-D-glucopyranosyl)uronate]-(1→4)-[2,3-di-O-benzyl-6-deoxy-6-C-(sulfonatomethyl)-α-D-glucopyranosyl]-
(1→4)-[sodium (2,3-di-O-methyl-α-L-idopyranosyl)uronate]-(1→4)-(2,3,6-tri-O-benzyl-α-D-glucopyranoside) 
(34). An amount of 0.5 M NaOH solution (2 mL) was added to the solution of compound 33 (206 mg, 
0.12 mmol) in a mixture of THF (2 mL) and MeOH (2 mL) and stirred at room temperature for 24 h. 
The reaction was quenched by the addition of 1 N HCl solution (1–2 drops) and the mixture was 
concentrated. The crude product was converted to sodium salt by ion exchange resin (Dowex, 
Molecules 2016, 21, 1497 16 of 18 
 
MeOH) to give 34 (187 mg, 90%) as a colourless syrup; Rf = 0.24 (8:2 CH2Cl2/MeOH); [α]D +42.81 (c 
0.10, CHCl3); 1H-NMR (360 MHz, CDCl3) δ 7.43–7.20 (m, 25H, arom.), 5.46 (d, J = 3.6 Hz, 1H), 5.15 (d, 
J = 3.3 Hz, 1H), 5.10 (d, J = 3.9 Hz, 1H), 5.04–4.48 (m, 14H, 2 × H-1, H-5-E, H-5-G, 10 × PhCH2), 4.09–
3.25 (m, 17H, skeleton protons), 3.58, 3.54, 3.53, 3.52, 3.50, 3.43, 3.35, 3.34 (8s, 24H, 8 × OCH3), 3.23–
3.16 (m, 1H), 3.09 (dd, 1H, H-2-D), 3.07–3.86 (m, 2H, H-7b-D, H-7b-F), 2.81 (t, J = 9.8 Hz, 1H, H-4-D), 
2.60–2.48 (m, 1H, H-6a), 2.33–2.19 (m, 1H, H-6a), 1.98–1.82 (m, 2H, H-6b-D, H-6b-F) ppm; 13C-NMR (101 
MHz, MeOD) δ 171.1, 170.7 (2 × CO), 140.4, 140.2, 139.6, 139.5, 139.5 (5C, Cq arom.), 129.4, 129.3, 129.2, 
129.0, 129.0, 128.8, 128.7, 128.6, 128.4, 128.2, 128.0 (25C, arom.), 104.6, 100.5, 98.9, 96.8, 96.7 (5 × C-1), 
87.0, 85.4, 84.5, 84.1, 82.9, 82.8, 81.3, 81.2, 80.8, 80.6, 80.4, 76.6, 75.2, 74.9, 74.1, 71.6, 71.5, 71.0, 70.7 (20C, 
skeleton carbons), 76.0, 75.8, 74.5, 73.9, 73.8 (5 × PhCH2), 69.6 (C-6-H), 61.2, 60.9, 60.6, 59.9, 59.5, 55.9, 
55.9, 55.6 (8 × OCH3), 30.7, 28.3 (C-6-D, C-6-F) ppm; MALDI-TOF MS: m/z 1685.49 [M + Na]+ (Calcd. 
1685.47); Anal. Calcd. for C75H94Na4O32S2 (1662.48): C, 54.15; H, 5.70; Na, 5.53; O, 30.78; S, 3.85. Found: 
C, 54.08; H, 5.67; S, 3.87. 
Methyl [2,3,4-tri-O-methyl-6-deoxy-6-C-sulfonatomethyl-α-D-glucopyranosyl]-(1→4)-[sodium (2,3-di-O-
methyl-β-D-glucopyranosyl)uronate]-(1→4)-[6-deoxy-6-C-sulfonatomethyl-α-D-glucopyranosyl]-(1→4)-
[sodium (2,3-di-O-methyl-α-L-idopyranosyl)uronate]-(1→4)-α-D-glucopyranoside (35). An amount of 10% 
Pd/C (110 mg) and acetic acid (350 μL) were added to the solution of compound 34 (180 mg, 0.11 
mmol) in 96 v/v % EtOH (10 mL). The mixture was stirred at room temperature for 24 h under a 10 
bar H2 atmosphere. The mixture was diluted with MeOH and the catalyst was filtered off on Celite-
pad. The filtrate was concentrated. The crude product was purified by column chromatography (7:6:1 
CH2Cl2/MeOH/H2O) and gel chromatography (Sephadex G-25, H2O) to give 35 (123 mg, 92%) as a 
colourless syrup; Rf = 0.25 (7:6:1 CH2Cl2/MeOH/H2O); [α]D +21.82 (c 0.21, CHCl3); 1H-NMR (360 MHz, 
CDCl3) δ 5.54 (s, 1H), 5.14 (s, 1H), 5.09 (s, 1H), 4.83 (s, 2H), 4.62 (s, 1H), 4.18 (s, 1H), 3.97–3.25 (m, 46H, 
skeleton protons, 8 × OCH3), 3.18–2.96 (m, 5H), 2.90 (d, J = 2.7 Hz, 1H), 2.49–2.35 (m, 1H, H-6a), 2.29–
2.16 (m, 1H, H-6a), 1.99–1.85 (m, 2H, H-6b, H-6b) ppm; 13C-NMR (91 MHz, CDCl3) δ 193.3, 193.2 (2 × 
CO), 103.5, 103.4, 100.1, 100.0, 96.2 (5 × C-1), 86.8, 84.4, 83.9, 83.5, 82.3, 81.8, 80.4, 78.6, 78.1, 76.7, 73.9, 
72.8, 72.6, 72.5, 72.4, 71.9, 71.6, 71.4, 70.3, 69.9 (20C, skeleton carbons), 61.2 (C-6-H), 61.5, 61.1, 60.4, 
60.4, 59.9, 59.6, 58.9, 55.9 (8 × OCH3), 48.3, 48.2 (C-7-D, C-7-F), 27.3, 27.0 (C-6-D, C-6-F) ppm; ESI-MS: 
m/z 561.46 [M + 2H]2− (Calcd. 561.15); Anal. Calcd. for C40H64Na4O32S2 (1212.24): C, 39.61; H, 5.32; Na, 
7.58; O, 42.21; S, 5.29. Found: C, 39.56; H, 5.29; S, 5.24. 
Nona sodium [methyl (2,3,4-tri-O-methyl-6-deoxy-6-C-sulfonatomethyl-α-D-glucopyranosyl)]-(1→4)- 
[2,3-di-O-methyl-β-D-glucopyranosyluronate]-(1→4)-[2,3-di-O-sulfonato-6-deoxy-6-C-sulfonatomethyl-α-
D-glucopyranosyl]-(1→4)-[2,3-di-O-methyl-α-L-idopyranosyluronate]-(1→4)-2,3,6-tri-O-sulfonato-α-D-
glucopyranoside (36). To the solution of compound 35 (58 mg, 0.047 mmol) in dry DMF (4 mL) sulfur 
trioxide–triethylamine complex (215 mg, 1.187 mmol) was added and the reaction mixture was 
stirred at 50 °C for 72 h. The reaction was quenched with satd. aq. NaHCO3 (262 mg, 3.12 mmol). The 
solution was concentrated. The crude product was treated with Dowex ion-exchange resin (Na+ 
form), and then purified by Sephadex G-25 column chromatography eluting with H2O to give 36 (28 
mg, 36%) as a white powder. Rf = 0.53 (7:4:1 CH2Cl2/MeOH/H2O); ESI-MS: m/z for C40H59Na9O47S7 
(1721.94): 837.771 [M − 2Na]2− (Calcd. 837.979); 794.136 [M − 6Na + 4H]2− (Calcd. 794.015). 
4. Conclusions 
Five new idraparinux-analogue pentasaccharide precursors bearing one or two primary 
sulfonatomethyl moieties at the D, F or H glucose units have been prepared using four disaccharides 
and two monosaccharides as the building blocks. The synthetic approach, including two subsequent 
glycosylation steps proved to be highly efficient, and the glycosylation reactions proceeded in good 
to excellent yields with complete stereoselectivity, regardless of the C-sulfonation pattern of the 
building blocks. 
Unexpectedly, the transformation of the protected pentasaccharides into the fully O-sulfated 
and O-methylated end-products was troublesome. Upon synthesis of pentasaccharide 29 from 9 via 
a Zemplén deacetylation, O-methylation, NAP-deprotection and TEMPO-BAIB oxidation route, the 
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glucuronide formation proceeded with low efficacy. Fortunately, pentasaccharide 6 could be converted 
into the desired disulfonic acid product in an acceptable yield by applying a reaction sequence in 
which the oxidative formation of the glucuronic acid residue preceded the introduction of the methyl 
ether groups. A study to improve the yields of the synthetic procedures at a pentasaccharide level is 
in progress in our laboratory. 
Synthesis of further isosteric sulfonic acid analogues of idraparinux and evaluation of their 
anticoagulant activity will be reported in due course. 
Supplementary Materials: Supplementary materials can be accessed at: http://www.mdpi.com/1420-3049/ 
21/11/1497/s1. copies of 1H-NMR and 13C-NMR spectra of described compounds. 
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